Pharma News

12 October 2021

Covaxin get emergency approval for children aged 2-18 years

The Subject Expert Committee (SEC) of CDSCO has granted emergency use approval (EUA) to Covaxin for children in the 2-18 years age group. Covaxin is developed by Hyderabad based Bharat Biotech.

Caovaxin had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the Drugs Controller General of India (DCGI) at the start of this month.

11 October 2021

Sandoz acquire cephalosporin business of GSK

Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.

Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.

11 October 2021

OSE Immunotherapeutics receives European patent for Tedopi, cancer vaccine

OSE Immunotherapeutics SA announced that it has received notice of allowance from the European Patent Office for a patent application related to Tedopi®, a neoepitope therapeutic vaccine, protecting a method for manufacturing a ready-to-use peptide emulsion for its use in the treatment of cancers in HLA-A2 positive patients. This patent will provide a protection until 2038.

11 October 2021

BRUKINSA approved for treatment of Patients with Mantle Cell Lymphoma

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

6 October 2021

Manganese makes its mark in drug synthesis

Rice chemist Julian West and graduate student Yen-Chu Lu found that an Earth-abundant salt of manganese further simplifies the process of synthesizing fluoroketones, precursor molecules for drug design and manufacture.

The complex method required catalysts of expensive silver until the West lab figured out how to replace it with a cerium-based compound. That in turn led the researchers to eye manganese as a next-level catalyst.

6 October 2021

Cancer chemotherapy drug reverses Alzheimer symptoms in mice

A drug commonly used to treat cancer can restore memory and cognitive function in mice that display symptoms of Alzheimer’s disease, new UBC research has found.

2 October 2021

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II). Hunter syndrome is caused by a deficiency of IDS and manifests in different forms.

2 October 2021

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

2 October 2021

NPPA condemns false statements regarding its connivance in any malpractices adopted by Pharmaceutical Companies

National Pharmaceutical Pricing Authority is a regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India and is committed to ensure affordability and accessibility of medicines by fixing the ceiling price for scheduled formulations and monitoring the prices of non-scheduled formulations.